Home LiteratureArticle Details
PMID: 11104782 Published · ppublish English Journal Article Comment

Unraveling the mechanism of action of thiazolidinediones.

The Journal of clinical investigation ·Vol. 106 ·No. 11 ·2000-12-00 ·Pages 1305-7

Kahn CR, Chen L, Cohen SE

Abstract

暂无摘要

MeSH Terms
Animals Chromans/therapeutic use Diabetes Mellitus, Type 2/drug therapy Humans Hypoglycemic Agents/therapeutic use Pioglitazone Rosiglitazone Thiazoles/therapeutic use Thiazolidinediones Troglitazone
Chemicals
Chromans Hypoglycemic Agents Thiazoles Thiazolidinediones Rosiglitazone Troglitazone Pioglitazone
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Kahn C R
Joslin Diabetes Center and Harvard Medical School, Boston, Massachusetts, USA. [email protected]
Chen L
Cohen S E
References (25)
25 references, click to expand
  1. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice.
    J Clin Invest. 2000 Feb;105(3):271-8 PMID: 10675352
  2. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes.
    Cell. 1999 Feb 5;96(3):329-39 PMID: 10025399
  3. Transcriptional regulation of adipogenesis.
    Genes Dev. 2000 Jun 1;14(11):1293-307 PMID: 10837022
  4. Insulin signaling and action in fat cells: associations with insulin resistance and type 2 diabetes.
    Ann N Y Acad Sci. 1999 Nov 18;892:119-26 PMID: 10842657
  5. Mechanism of insulin resistance in A-ZIP/F-1 fatless mice.
    J Biol Chem. 2000 Mar 24;275(12):8456-60 PMID: 10722680
  6. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance.
    Mol Cell. 1998 Nov;2(5):559-69 PMID: 9844629
  7. Life without white fat: a transgenic mouse.
    Genes Dev. 1998 Oct 15;12(20):3168-81 PMID: 9784492
  8. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes.
    Ann Intern Med. 2000 Aug 15;133(4):263-74 PMID: 10929166
  9. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction.
    Mol Cell. 2000 Jul;6(1):87-97 PMID: 10949030
  10. Insights into insulin resistance and type 2 diabetes from knockout mouse models.
    J Clin Invest. 2000 Aug;106(4):459-65 PMID: 10953020
  11. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists.
    J Clin Invest. 2000 Aug;106(4):467-72 PMID: 10953021
  12. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones.
    J Clin Invest. 2000 Nov;106(10):1221-8 PMID: 11086023
  13. Free fatty acids and pathogenesis of type 2 diabetes mellitus.
    Trends Endocrinol Metab. 2000 Nov;11(9):351-6 PMID: 11042464
  14. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats.
    Diabetes. 1988 Nov;37(11):1549-58 PMID: 3053303
  15. In vitro studies on the action of CS-045, a new antidiabetic agent.
    Metabolism. 1990 Oct;39(10):1056-62 PMID: 2120548
  16. Adipocyte fatty acid-binding protein: regulation of gene expression in vivo and in vitro by an insulin-sensitizing agent.
    Mol Pharmacol. 1992 Oct;42(4):558-62 PMID: 1435736
  17. Targeted expression of a toxin gene to adipose tissue: transgenic mice resistant to obesity.
    Genes Dev. 1993 Jul;7(7B):1318-24 PMID: 8330737
  18. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer.
    Genes Dev. 1994 May 15;8(10):1224-34 PMID: 7926726
  19. Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells.
    Mol Pharmacol. 1994 Dec;46(6):1070-6 PMID: 7808426
  20. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma).
    J Biol Chem. 1995 Jun 2;270(22):12953-6 PMID: 7768881
  21. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma.
    Cell. 1995 Dec 1;83(5):803-12 PMID: 8521497
  22. Thiazolidinediones in the treatment of insulin resistance and type II diabetes.
    Diabetes. 1996 Dec;45(12):1661-9 PMID: 8922349
  23. Troglitazone action is independent of adipose tissue.
    J Clin Invest. 1997 Dec 1;100(11):2900-8 PMID: 9389757
  24. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
    N Engl J Med. 1998 Mar 26;338(13):867-72 PMID: 9516221
  25. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats.
    J Clin Invest. 1998 Mar 15;101(6):1354-61 PMID: 9502777
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
0021-9738
DOI
10.1172/JCI11705
Email
[email protected]
Published
2000-12-00
Pages
1305-7
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC387251
Subset
IM
Corrections
CommentOn
PMID: 10953020
CommentOn
PMID: 10953021
CommentOn
PMID: 11086023
External Links
PubMed source DOI: 10.1172/JCI11705 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2